A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy

Published:2018-01 Issue: Volume:144 Page:1-28
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Yin Lei,Li Heng,Liu Wenjian,Yao Zhenglin,Cheng Zhenzhen,Zhang Huabei,Zou Hui

Funder

Development of Significant New Drugs program

Natural Science Foundation of China

the Science and Technology Support Program

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference53 articles.

1. Recurrent glioblastoma: where we stand;Roy;South Asian J. Cancer,2015

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N. Engl. J. Med.,2005

3. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme;Cohen;Clin. Cancer Res.,2005

4. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis;Chowdhary;J. Neurooncol.,2015

5. DNA damage check point recovery and cancer development;Wang;Exp. Cell Res.,2015

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a potent CDKs/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML;European Journal of Medicinal Chemistry;2024-09

2. Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer;Current Signal Transduction Therapy;2024-07

3. Synthesis of Spiroindolenines by Iodine‐Mediated Dearomative Aza‐Spirocyclization of Indoles;Advanced Synthesis & Catalysis;2024-03-19

4. Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine;Advanced Science;2024-02-28

5. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer;Frontiers in Oncology;2024-01-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3